ABSTRACT
Background The Triglyceride-glucose (TyG) index is an emerging marker for insulin resistance and metabolic syndrome. Helicobacter pylori, a bacterium associated with gastrointestinal diseases, may also influence metabolic risk profiles. This study aimed to investigate the relationship between the TyG index and Helicobacter pylori infection among a representative sample of adults.
Methods A total of 9965 participants from the NHANES 1999-2000 cycle were involved from March 1, 1999, to December 1, 2000.A cross-sectional analysis was conducted on 3797 participants. The baseline characteristics according to the quartile of the TyG index were evaluated.Multivariate binary logistic regression models were constructed to analyze the independent effects of the TyG index on Helicobacter pylori infection. A two-piecewise binary logistic regression model was used to explore the non-linear relationship between the TyG index and Helicobacter pylori, with an inflection point identified. Subgroup analyses were performed to assess the trends of effect sizes across different variables including age, sex, glucose levels, body mass index (BMI), and chronic kidney disease (CKD).
Results Multivariate analysis indicated a linear relationship between the TyG index and Helicobacter pylori infection, suggesting differential influence of the TyG index on Helicobacter pylori infection. Subgroup analysis demonstrated significant interactions only for a few variables, with all p-values for interaction below 0.05.
Conclusions The study suggests a linear association between the TyG index and Helicobacter pylori infection.These findings have implications for understanding the metabolic influences on Helicobacter pylori infection and may guide targeted interventions for at-risk populations.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://www.cdc.gov/nchs/nhanes/index.htm
Funding Statement
This work was supported by National Natural Science Foundation of China (Grant No. 82373270),Guizhou Provincial Department of Science and Technology Natural Science Foundation(No Foundation-ZK[2022]),Guizhou Provincial Health Commission Science and Technology Fund(No.gzwkj2023-135),and science Foundation of 925th hospital( No. 2023[3]),(No. 2022[3/4])
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used (or will use) ONLY openly available human data that were originally located at:https://www.cdc.gov/nchs/nhanes/index.htm
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors All data produced in the present work are contained in the manuscript All data produced are available online
